The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The following chart illustrates this accelerating growth in Signatera clinical testing: Natera’s gross margin improved to 63% in Q1 2025, up from 57% in Q1 2024, reflecting the company’s continued ...
Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer This real-world study analyzed 267 ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual ...
SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
Q1 2026 Management view "We posted revenues of $697 million in Q1, 39% growth over last year." (CEO & Director Steve Chapman) "Q1 was our first to deliver 1 million units in a single quarter headlined ...
AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...
Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, ...
AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for ...
Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Testicular cancer represents approximately 95% of all GCTs 1 and is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results